Showing results (91-100 of 143) with videos related to

Sort By:
Pageof 15
BMJ Open|June 1, 2022
Adverse events and overall health and well-being after COVID-19 vaccination: interim results from the VAC4COVID cohort safety studyAmy Rogers, Evelien Rooke, Steve Morant, et al.
Journal of the American College of Cardiology|August 28, 2012
Improving the primary prevention of cardiovascular events by using biomarkers to identify individuals with silent heart diseaseM Adnan Nadir, Sushma Rekhraj, Li Wei, et al.
American Heart Journal|September 20, 2005
Effects of eplerenone versus losartan in patients with low-renin hypertensionMyron H Weinberger, William B White, Luis-Miguel Ruilope, et al.
American Journal of Hypertension|October 21, 2020
Rationale and Design of the Genotype-Blinded Trial of Torasemide for the Treatment of Hypertension (BHF UMOD)Linsay McCallum, Katriona Brooksbank, Alex McConnachie, et al.
Journal of Hypertension|July 4, 2019
Allopurinol treatment adversely impacts left ventricular mass regression in patients with well-controlled hypertensionChristopher R Gingles, Ruth Symon, Stephen J Gandy, et al.
Seminars in Arthritis and Rheumatism|February 25, 2014
Up-titration of allopurinol in patients with goutClaudine G Jennings, Isla S Mackenzie, Rob Flynn, et al.
Pharmacoepidemiology and Drug Safety|December 5, 2002
The safety of drugs for OTC use: what evidence is required for an NSAID switch?Thomas M MacDonald, Keith Beard, Rudolf Bruppacher, et al.
The Journal of Clinical Endocrinology and Metabolism|September 6, 2002
Variation at the aldosterone synthase (CYP11B2) locus contributes to hypertension in subjects with a raised aldosterone-to-renin ratioPitt O Lim, Thomas M Macdonald, Christine Holloway, et al.
Antioxidants (Basel, Switzerland)|August 26, 2022
The Prognostic Value of Derivatives-Reactive Oxygen Metabolites (d-ROMs) for Cardiovascular Disease Events and Mortality: A ReviewFilippo Pigazzani, Davide Gorni, Kenneth A Dyar, et al.
BMJ Open|August 9, 2015
Comparison of single and combination diuretics on glucose tolerance (PATHWAY-3): protocol for a randomised double-blind trial in patients with essential hypertensionMorris J Brown, Bryan Williams, Thomas M MacDonald, et al.
Pageof 15